PARTNER
IN ASTHMA
CARE

PARTNER
IN ASTHMA
RELIEF

DUPIXENT is a biologic indicated as an add-on maintenance treatment in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype
or with oral corticosteroid dependent asthma. Limitation of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.1

SEE IF DUPIXENT CAN HELP YOUR
APPROPRIATE ASTHMA PATIENTS GAIN CONTROL

DUPIXENT MAY BE
APPROPRIATE FOR

your moderate-to-severe asthma patients with an eosinophilic phenotype or who are OCS-dependent. These patients may present with any of the following despite current therapy1:

  • Exacerbation requiring hospitalization/ED visit in the past year
  • 2 courses of oral corticosteroids (OCS) in the past year despite maximum inhaler therapy
  • Still uncontrolled on medium- or high-dose inhaled corticosteroids (ICS) + LABA
  • Elevated EOS with or without IgE/FeNO
  • Impaired lung function and decreased quality of life
DUPIXENT MAY OFFER
SYMPTOM RELIEF TO YOUR
APPROPRIATE ASTHMA
PATIENTS, INCLUDING:

Allergic asthma
patients with
elevated eosinophils

OCS-dependent asthma patients—DUPIXENT
is the only biologic
indicated for this
patient population1

Patients with coexisting diseases, such as atopic dermatitis or chronic rhinosinusitis with nasal polyposis1,2

EXPLORE PATIENT TYPES

Extensive clinical trial and real-world experience across indications

>10,000 patients studied and >300K patient prescriptions3,4

VIEW OTHER INDICATIONS

DUPIXENT has proven efficacy and demonstrated safety in nearly 3000 patients with moderate-to-severe asthma1

Exacerbation reduction1

SEE THE DATA

OCS reduction5

SEE THE DATA

Rapid and sustained
breathing relief1,6,a

SEE THE DATA

Demonstrated
safety profile1

SEE SAFETY DATA

Asthma control
and quality of life1

SEE THE DATA

At home or in-office
administration1,b

SEE OPTIONS

a ~72% of the total FEV1 improvement was seen at Week 2 with DUPIXENT 200 mg + SOC (n=264). Up to 470 mL improvement from baseline in pre-bronchodilator FEV1 at Week 52 with DUPIXENT 200 mg + SOC (n=264) vs 170 mL with placebo + SOC (n=148) (Trial 2, EOS ≥300 cells/µL, secondary endpoint). 320 mL improvement from baseline in pre-bronchodilator FEV1 at Week 12 with DUPIXENT 200 mg + SOC (n=631) vs 180 mL with placebo + SOC (n=317) (LSM difference: 140 mL [95% CI: 80, 190 mL]) (Trial 2, ITT population, primary endpoint). In Trial 2, a significant difference from placebo + SOC was not observed at 12 weeks in change in pre-bronchodilator FEV1 in patients with baseline blood eosinophil levels <150 cells/µL taking DUPIXENT 200 mg + SOC.1

b A patient or caregiver may inject DUPIXENT after training in subcutaneous injection technique.1

Most Common
Adverse Reactions

The most common adverse reactions (incidence ≥1%) in patients with asthma were injection site reactions, oropharyngeal pain, and
eosinophilia. In Trials 1 and 2, the proportion of subjects who discontinued treatment due to adverse events was 4% of the placebo + SOC
group, 3% of the DUPIXENT 200 mg Q2W + SOC group, and 6% of the DUPIXENT 300 mg Q2W + SOC group.1

Trial Designs and Results

DUPIXENT is not a steroid1,f

fDupilumab is a dual inhibitor of IL-4 and IL-13 signaling. The mechanism of dupilumab action in asthma has not been definitively established.

Frequently asked questions about DUPIXENT

DUPIXENT is a biologic therapy and has a unique mechanism of action. DUPIXENT is the first and only dual inhibitor of IL-4 and IL-13 signaling, inhibiting two key sources of Type 2 inflammation in asthma. DUPIXENT is not an immunosuppressant or steroid. The mechanism of dupilumab action in asthma has not been established.1

SEE HOW DUPIXENT WORKS

DUPIXENT is indicated as an add-on maintenance treatment in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid dependent asthma. It is the only biologic indicated for an OCS-dependent asthma population. Limitation of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.1

SEE THE EFFICACY AND SAFETY DATA OF DUPIXENT EXPLORE APPROPRIATE PATIENT TYPES

DUPIXENT is typically prescribed by a specialist, such as an allergist or pulmonologist. If you have a patient aged 12 years or older with moderate-to-severe asthma with an eosinophilic phenotype, or with OCS-dependent asthma, who you think might be appropriate for DUPIXENT, consider referring them to an asthma specialist.1

For help finding a specialist in your area, use the Healthgrades® tool below.

Overall, 98% of commercially insured patients nationally are covered for DUPIXENT.7,g Coverage varies by type and plan.

With the DUPIXENT formulary status tool, you can see which insurance plans offer coverage for DUPIXENT in your area. Contact the health plan or DUPIXENT MyWay® to verify coverage for a specific patient.

gMMIT Lives as of April 2021.

CHECK FORMULARY STATUS FOR DUPIXENT IN YOUR AREA

For patients with a valid prescription for DUPIXENT, support is available through the DUPIXENT MyWay® patient support program. Patients who enroll can receive:

  • Insightful tips and tools to help them along the way
  • Supplemental injection training virtually or over the phone
  • Financial assistance for eligible patients
  • Assistance with insurance questions
  • Assistance locating a specialty pharmacy that can dispense DUPIXENT
LEARN MORE ABOUT THE SUPPORT OFFERED BY DUPIXENT MyWay

DUPIXENT provides eligible patients with access supportg,h

We are committed to helping ensure patients have access to DUPIXENT and are provided with assistance in navigating the insurance process

Overall, 98% of commercially insured patients nationally are covered for DUPIXENT.7,g

Coverage varies by type of plan.

Find out more

gMMIT Lives as of April 2021.

hEligible patients subject to program restrictions.

iTHIS IS NOT INSURANCE. Program has an annual maximum of $13,000. Not valid for prescriptions paid, in whole or in part, by Medicaid, Medicare, VA, DOD, TRICARE, or other federal or state programs, including any state pharmaceutical assistance programs. This program is not valid where prohibited by law, taxed, or restricted. DUPIXENT MyWay reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. Additional terms and conditions apply. Any savings provided by this program may vary depending on patients' out-of-pocket costs. Upon registration, patients will receive all program details.

Refer your appropriate asthma patients to a specialist today

Partner with an asthma specialist to help your patients. Use the Healthgrades®
tool to easily find nearby specialists.

Sanofi US and Regeneron neither endorse nor recommend any particular physician, and
search results do not include a comprehensive list of doctors in your area.

ED, emergency department; EOS, eosinophils; FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in one second; ICS, inhaled corticosteroids; ITT, intention-to-treat; LABA, long-acting beta agonist; LSM, least squares mean; Q2W, once every 2 weeks; SOC, standard of care.

References:

  1. DUPIXENT Prescribing Information.
  2. Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50.
  3. Data on file, Sanofi Genzyme and Regeneron, US. LH Patient View file dated 2/3/21 (data through December 31, 2020).
  4. Data on file, Regeneron Pharmaceuticals, Inc.
  5. Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475-2485.
  6. Santanello NC, Zhang J, Seidenberg B, Reiss TF, Barber BL. What are minimal important changes for asthma measures in a clinical trial? Eur Respir J. 1999;14(1):23-27.
  7. The Dedham Group Quality of Access Tracking Report. April 2021.

Important Safety
Information and Indications

CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity: Hypersensitivity reactions, including generalized urticaria, rash, erythema nodosum, anaphylaxis and serum sickness or serum sickness-like reactions, were reported in <1% of subjects who received DUPIXENT in clinical trials. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

Conjunctivitis and Keratitis: Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received DUPIXENT with conjunctivitis being the most frequently reported eye disorder in these patients. Conjunctivitis also occurred more frequently in chronic rhinosinusitis with nasal polyposis subjects who received DUPIXENT. Advise patients to report new onset or worsening eye symptoms to their healthcare provider.

Eosinophilic Conditions: Patients being treated for asthma may present with serious systemic eosinophilia sometimes presenting with clinical features of eosinophilic pneumonia or vasculitis consistent with eosinophilic granulomatosis with polyangiitis (EGPA), conditions which are often treated with systemic corticosteroid therapy. These events may be associated with the reduction of oral corticosteroid therapy. Physicians should be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients with eosinophilia. Cases of eosinophilic pneumonia were reported in adult patients who participated in the asthma development program and cases of vasculitis consistent with EGPA have been reported with DUPIXENT in adult patients who participated in the asthma development program as well as in adult patients with co-morbid asthma in the CRSwNP development program. A causal association between DUPIXENT and these conditions has not been established.

Acute Asthma Symptoms or Deteriorating Disease: Do not use DUPIXENT to treat acute asthma symptoms, acute exacerbations, acute bronchospasm or status asthmaticus. Patients should seek medical advice if their asthma remains uncontrolled or worsens after initiation of DUPIXENT.

Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical, or inhaled corticosteroids abruptly upon initiation with DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Patients with Co-Morbid Asthma: Advise patients with atopic dermatitis or CRSwNP who have co-morbid asthma not to adjust or stop their asthma treatments without consultation with their physicians.

Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves.

ADVERSE REACTIONS:
  • Atopic dermatitis: The most common adverse reactions (incidence ≥1% at Week 16) in adult patients are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, and dry eye. The safety profile in children and adolescents through Week 16 was similar to that of adults with atopic dermatitis. In an open-label extension study, the long-term safety profile of DUPIXENT in adolescents and children observed through Week 52 was consistent with that seen in adults with atopic dermatitis.
  • Asthma: The most common adverse reactions (incidence ≥1%) are injection site reactions, oropharyngeal pain, and eosinophilia.
  • Chronic rhinosinusitis with nasal polyposis: The most common adverse reactions (incidence ≥1%) are injection site reactions, eosinophilia, insomnia, toothache, gastritis, arthralgia, and conjunctivitis.

DRUG INTERACTIONS: Avoid use of live vaccines in patients treated with DUPIXENT.

USE IN SPECIFIC POPULATIONS
  • Pregnancy: There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. Healthcare providers and patients may call 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/dupixent/ to enroll in or obtain information about the registry. Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.
  • Lactation: There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.

Please see accompanying full Prescribing Information

Indications

Atopic Dermatitis: DUPIXENT is indicated for the treatment of patients aged 6 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

Asthma: DUPIXENT is indicated as an add-on maintenance treatment in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid dependent asthma. Limitation of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.

Chronic rhinosinusitis with nasal polyposis (CRSwNP): DUPIXENT is indicated as an add-on maintenance treatment in adult patients with inadequately controlled CRSwNP.